Key Points bioAffinity Technologies is advancing CyPath® Lung for use in monitoring lung cancer survivors after treatment. The noninvasive sputum-based test is designed to provide…
September 01, 2026
August 31, 2026
Numinus Wellness Reports 29% Quarterly Revenue Growth as Practitioner Training Accelerates
Key Points Q4 fiscal 2025 revenue increased 29% sequentially to C$2.33 million. Gross profit rose 63.5% from the prior quarter to C$1.42 million. Gross margin…
Key Points Verrica completed enrollment in COVE-2, its first pivotal Phase 3 trial of YCANTH for common warts. A blinded, per-protocol statistical power analysis found…
August 26, 2026
FDA Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer, Months Ahead of Schedule
Key Points The FDA approved daraxonrasib under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic…
Key Points New sleep apnea patient referrals at Vivos’ Nevada centers increased 212% over the latest six-week period compared with the prior six weeks. Average…
Key Points The V007 study enrolled 242 U.S. patients with end-stage kidney disease who needed new vascular access for hemodialysis. At six months, 81.3% of…
Key Points AvMEDICAL will market CyPath Lung through its national sales team and established federal procurement network. The agreement targets VA medical centers and other…
Key Points CareCloud will develop LailaCare, a customized AI-powered platform for KabaFusion’s home infusion and specialty pharmacy operations. The platform is intended to combine referral intake,…
August 14, 2026
Capricor Stock Rallies as FDA Opens Path for Revised Deramiocel Filing in Duchenne Muscular Dystrophy
Key Points Capricor Therapeutics, Inc. plans to amend its biologics license application, or BLA, for deramiocel after an FDA advisory committee voted 9–3 against the…
August 14, 2026
Allogene’s ALPHA3 Data and FDA Designations Sharpen the Case for Cema-Cel in Lymphoma
Key Points Allogene Therapeutics reported Q2 2026 results and a business update, highlighted by an interim futility analysis in the pivotal ALPHA3 trial of cema-cel…
The planned 800-patient U.S. study will test an oral FASN inhibitor in moderate to severe acne, including approximately 450 adolescents. Sagimet Biosciences (Nasdaq: SGMT) is…
Key Points Alterity Therapeutics received a new U.S. composition-of-matter patent covering a crystalline mesylate form of ATH434, its lead treatment candidate for multiple system atrophy….